euro adhoc: Intercell AG / Annual Reports / Intercell AG announces Q2/ H1 2008 results and gives update on business (E)

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

18.08.2008

» International approval processes for Japanese Encephalitis vaccine
on schedule - Approvals of Intercell´s Japanese Encephalitis vaccine
candidate in the US, Europe and Australia expected within the next few
months

» Acquisition of Iomai Corporation (Iomai) closed according to plan

» Despite higher costs because of Iomai acquisition profitability expected
for full year 2008

» Revenues increased to EUR 17.6 m in H1 2008 compared EUR 5.2 m in
H1 2007 (240.3 percent) - Net loss decreased by EUR 6.9 m (44.4 percent),
to EUR 8.6 m in H1 2008 from EUR 15.6 m in H1 2007 -
Strong cash position with EUR 258.3 m by the end of H1 2008

Vienna (Austria), August 18, 2008 - Today Intercell AG (VSE: ICLL) announced the
financial results for Q2 / H1 2008 and released an update on the company´s
developmental programs and strategy.

Following the completion of US FDA pre-approval inspection, Intercell continues
to work towards approvals of its Japanese Encephalitis vaccine candidate in the
US, Europe and Australia within the next few months

» FDA waives VRPAC (Vaccines and Related Biological Products Advisory
Committee); pre-approval inspection completed on time

» Licensure application submitted to Australian Therapeutic Goods
Administration (TGA) and to Canadian Division of Biologics and Genetic
Therapies Directorate of Health. TGA grants priority review for Intercell's
vaccine candidate in Australia

» Intercell already produces the vaccine at its manufacturing facility in
Livingston under the commercial Manufacturer's License from MHRA

» Vaccine demonstrates excellent safety and immunogenicity at "half dose" in
Phase II trials in children. Development for endemic markets with
Intercell's Indian partner Biological E. progresses well

» Ongoing strategic assessment of potential opportunities on the Japanese
market continues

Intercell acquires Iomai and strengthens leadership in vaccine innovation -
first focusing on bringing the vaccine patch for Traveler's Diarrhea to market

» Intercell's acquisition of Iomai closed smoothly on August 5, 2008. The
total consideration of 1,442,819 Intercell shares and a cash component of
EUR 75 million (USD 116 million), was comfortably financed from existing
reserves

» Valuable expansion of Intercell's pipeline and leveraging of Intercell's
late-stage product development with two further programs in late-stage
clinical development - the vaccine patch for Traveler's Diarrhea (start of
Phase III planned for the first half of 2009) and the vaccine enhancement
patch for the Pandemic Flu (start of Phase II in 2008)

Hospital-acquired infections - all developmental programs on track

» S. aureus: Phase II of the vaccine in elective cardiothoracic surgery -
conducted by Merck & Co - progressing (conducted by Merck & Co., Inc.)

» Pseudomonas: Start of clinical Phase II/III trials expected for 2008

» Pneumococcus: Outstanding pre-clinical results on the novel, protein-based,
universal vaccine published in the Journal of Experimental Medicine;
initiation of Phase I trials planned for 2008

Adjuvant IC31® - Progress in the development of new Influenza vaccine - Sanofi
Pasteur joins Tuberculosis cooperation

» Influenza: Novartis initiated clinical trials for the seasonal flu vaccine
containing IC31®

» Tuberculosis: The tuberculosis vaccine, currently being tested in clinical
trials (formulated with IC31®), will be further developed in a partnership
between Statens Serum Institut (SSI) and Sanofi Pasteur

Financial Statement

» Revenues increased to EUR 17.6 m in H1 2008 compared EUR 5.2 m in H1 2007,
or by 240.3 percent. Net loss decreased by EUR 6.9 m, or by 44.4 percent, to
EUR 8.6 m in H1 2008 from EUR 15.6 m in H1 2007. Strong cash position with
EUR 258.3 m by the end of H1 2008

Management Board

» Intercell's CSO, Alexander von Gabain, appointed to the Governing Board of
the European Institute of Innovation and Technology

KEY FIGURES

in EUR thousands 3 months 6 months Year
ended ended ended
June 30, June 30, Dec 31,
2008 2007 2008 2007 2007

Revenues 9,018 3,682 17,642 5,184 53,349

Net profit/(loss) (4,032) (8,522) (8,650) (15,571) 5,009

Net operating
cash flow (12,578) (4,867) (25,386) (14,502) (41,686)

Cash and marketable
securities,
end of period 258,286 81,056 258,268 81,056 257,571

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
lmalfent@intercell.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: Intercell AG
Campus Vienna Biocenter 6
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wiener Börse AG
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print